🇺🇸 FDA
Pipeline program

Sonelokimab

M1095-PPP-201

Phase 2 small_molecule active

Quick answer

Sonelokimab for Palmoplantar Pustulosis is a Phase 2 program (small_molecule) at MoonLake Immunotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
MoonLake Immunotherapeutics
Indication
Palmoplantar Pustulosis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials